Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 254

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer

Cybulski, Cezary, Wokołorczyk, Dominika, Jakubowska, Anna, Huzarski, Tomasz, Byrski, Tomasz, Gronwald, Jacek, Masojć, Bartłomiej, Dębniak, Tadeusz, Górski, Bohdan, Blecharz, Paweł, Narod, Steven A., Lubiński, Jan·2011·Journal of Clinical Oncology

Abstract

Purpose: To estimate the risk of breast cancer in a woman who has a CHEK2 mutation depending on her family history of breast cancer. Patients and Methods: Seven thousand four hundred ninety-four BRCA1 mutation–negative patients with breast cancer and 4,346 control women were genotyped for four founder mutations in CHEK2 (del5395, IVS2+1G>A, 1100delC, and I157T). Results: A truncating mutation (IVS2+1G>A, 1100delC, or del5395) was present in 227 patients (3.0%) and in 37 female controls (0.8%; odds ratio [OR], 3.6; 95% CI, 2.6 to 5.1). The OR was higher for women with a first- or second-degree relative with breast cancer (OR, 5.0; 95% CI, 3.3 to 7.6) than for women with no family history (OR, 3.3; 95% CI, 2.3 to 4.7). If both a first- and second-degree relative were affected with breast cancer, the OR was 7.3 (95% CI, 3.2 to 16.8). Assuming a baseline risk of 6%, we estimate the lifetime risks for carriers of CHEK2 truncating mutations to be 20% for a woman with no affected relative, 28% for a woman with one second-degree relative affected, 34% for a woman with one first-degree relative affected, and 44% for a woman with both a first- and second-degree relative affected. Conclusion: CHEK2 mutation screening detects a clinically meaningful risk of breast cancer and should be considered in all women with a family history of breast cancer. Women with a truncating mutation in CHEK2 and a positive family history of breast cancer have a lifetime risk of breast cancer of greater than 25% and are candidates for magnetic resonance imaging screening and for tamoxifen chemoprevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.34.0778

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 254

Metadata

Authors
Cybulski, C., Wokołorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Masojć, B., Dębniak, T., Górski, B., Blecharz, P., Narod, S. A., & Lubiński, J.
Venue
Journal of Clinical Oncology
Published
2011-10-01
Volume
29
Issue
28
Pages
3747-3752
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2162500120
Cited by
254
References
34
FWCI
6.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2010.34.0778
The paper
Cybulski, C., Wokołorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., Masojć, B., Dębniak, T., Górski, B., Blecharz, P., Narod, S. A., & Lubiński, J. (2011). Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.34.0778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.